Table 3.
Preferred pharmacological treatment for PHPT
| Ranking, 1–6 (mean) |
|||||
|---|---|---|---|---|---|
| France | Germany | UK | Italy | Spain | |
| Bisphosphonate | 1 (1.91) | 1 (1.88) | 1 (1.68) | 1 (1.99) | 1 (1.90) |
| Calcimimetics | 2 (2.53) | 2 (2.63) | 2 (3.24) | 2 (3.24) | 2 (3.01) |
| Furosemide | 3 (3.91) | 3 (3.61) | 3 (3.89) | 3 (3.89) | 3 (3.83) |
| Combination | 6 (4.41) | 4 (3.79) | 4 (3.94) | 5 (3.94) | 6 (4.11) |
| Oestrogen receptor agonists | 4 (4.04) | 5 (4.39) | 6 (4.19) | 6 (4.01) | 4 (4.10) |
| Oestrogen treatment | 5 (4.20) | 6 (4.71) | 5 (4.05) | 4 (3.93) | 5 (4.05) |
Values are rankings (1 representing the most frequently preferred treatment and 6 the least preferred treatment) based on the median ranking of each treatment modality by country. The mean ranking is provided in parentheses.